Filing Flows › Korsana Biosciences (KRSA) › Q3 2025 › vs Q3 2024
Korsana Biosciences (KRSA) Q3 2025 vs Q3 2024 (year over year)
Korsana Biosciences's revenue rose $681K (+351%) from $194K in Q3 2024 to $875K in Q3 2025. The biggest changes: Purchase Agreement +$800K (—); Option Agreement −$119K (-61%).
Korsana Biosciences, Q3 2025: revenue $875K (+351% year over year), operating margin -115.0%, net loss $976K, operating cash flow −$264K. The chart draws each line against Q3 2024, the increases inside each band.
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Purchase Agreement | $800K | $0 | $800K | — |
| Option Agreement | $75K | $194K | −$119K | -61% |
| Revenue | $875K | $194K | $681K | +351% |
| Other income, net | $30K | $405K | −$375K | -93% |
| Net loss | $976K | $723K | $253K | +35% |
| Costs & expenses | $1.9M | $1.3M | $559K | +42% |
| Operating costs | $1.9M | $1.3M | $559K | +42% |
| Research & development | $348K | $81K | $267K | +330% |
| General & admin | $1.5M | $1.2M | $292K | +24% |
| Operating cash sources | $976K | $723K | $253K | +35% |
| Share-based compensation | $118K | $138K | −$20K | -14% |
| Working capital & other | $594K | −$1.1M | $1.7M | — |
| Cash used in operations | $264K | $1.7M | −$1.5M | -85% |
| Net loss absorbed | $976K | $723K | $253K | +35% |
Questions
How much did Korsana Biosciences's revenue grow year over year in Q3 2025?
Korsana Biosciences's revenue rose $681K (+351%) from $194K in Q3 2024 to $875K in Q3 2025.
What drove Korsana Biosciences's revenue change in Q3 2025?
Purchase Agreement +$800K (—); Option Agreement −$119K (-61%).